

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kanstrup et al.

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: July 17, 2003

Examiner: To Be Assigned

For: Heterocyclic Compounds, which are Inhibitors of the Enzyme DPP-IV

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were cited to, or by, the USPTO in USSN 09/935,149 filed August 22, 2001, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. U.S. Patent 6,124,305;
2. WO 98/19998;
3. WO 00/34241;
4. WO 99/38501;
5. Holst et al., Diabetes, Vol. 47, pgs. 1663-1670 (1998);
6. U.S. Patent 3,896,119;
7. Abstract of Kubota et al., Yakugaku Zasshi, Vol. 89, pgs. 441-445 (1969);
8. Abstract of Kleine et al., Arzneim.-Forsch., Vol. 19, pgs. 1854-1855 (1969);

9. Abstract of Romanenko et al., Farm. Zh. (Kiev), Vol. 5, pgs. 41-44 (1986);
10. Abstract of Samura et al., Khim.-Farm. Zh., Vol. 20, pgs. 52-55 (1986);
11. Abstract of Gorczyca et al., Farmaco, Ed. Sci., Vol. 29, pgs. 802-810 (1974);
12. Abstract of Zimmer et al., Eur. J. Org. Chem., Vol. 9, pgs. 2419-2428 (1999);
13. Abstract of Gutorov et al., Khim.-Farm. Zh., Vol. 10, pgs. 61-64 (1976);
14. Abstract of Cygankiewicz et al., Acta Pol. Pharm., Vol. 34, pgs. 607-612 (1977);
15. Abstract of Khaliullin et al., Bashk. Khim. Zh., Vol. 4, pgs. 59-62 (1997);
16. Abstract of Martinson et al., Mol. Pharmacol., Vol. 31, pgs. 247-252 (1987);
17. Abstract of Skul'skaya et al., Farm. Zh. (Kiev), Vol. 4, pgs. 34-39 (1989);
18. Abstract of Mazur et al., Farm. Zh. (Kiev), Vol. 3, pgs. 82-84 (1996);
19. Abstract of Gorczyca et al., Acta Pol. Pharm., Vol. 39, pgs. 315-321 (1982);
20. WO 91/07945; and
21. WO 92/05175.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: July 17, 2003

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6197.214-US	Serial No. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Kanstrup et al.	
(Use several sheets if necessary)		Filing Date July 17, 2003	Group To be assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6197.204-US

Serial No. To Be Assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Kanstrup et al.

Filing Date July 17, 2003

Group To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,896,119	07-1975	Klingler, Karl-Heinz			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 91/07945	06/13/91	WIPO				X
		WO 92/05175	04/02/92	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Abstract of Kubota et al., Yakugaku Zasshi, Vol. 89, pgs. 441-445 (1969)
		Abstract of Kleine et al., Arzneim.-Forsch., Vol. 19, pgs. 1854-1855 (1969)
		Abstract of Romanenko et al., Farm. Zh. (Kiev), Vol. 5, pgs. 41-44 (1986)
		Abstract of Samura et al., Khim.-Farm. Zh., Vol. 20, pgs. 52-55 (1986)
		Abstract of Gorczyca et al., Farmaco, Ed. Sci., Vol. 29, pgs. 802-810 (1974)
		Abstract of Zimmer et al., Eur. J. Org. Chem., Vol. 9, pgs. 2419-2428 (1999)
		Abstract of Gutorov et al., Khim.-Farm. Zh., Vol. 10, pgs. 61-64 (1976)
		Abstract of Cygankiewicz et al., Acta Pol. Pharm., Vol. 34, pgs. 607-612 (1977)
		Abstract of Khaliullin et al., Bashk. Khim. Zh., Vol. 4, pgs. 59-62 (1997)
		Abstract of Martinson et al., Mol. Pharmacol., Vol. 31, pgs. 247-252 (1987)
		Abstract of Skul'skaya et al., Farm. Zh. (Kiev), Vol. 4, pgs. 34-39 (1989)
		Abstract of Mazur et al., Farm. Zh. (Kiev), Vol. 3, pgs. 82-84 (1996)
		Abstract of Gorczyca et al., Acta Pol. Pharm., Vol. 39, pgs. 315-321 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.